Price
CHART BY
Frequently asked questions
What is Biogen's market capitalization?
The market capitalization of Biogen is $32.63B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Biogen's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Biogen is 39.11. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Biogen?
Biogen's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $5.647. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Biogen's stock?
Currently, 36 analysts cover Biogen's stock, with a consensus target price of $238.93. Analyst ratings provide insights into the stock's expected performance.
What is Biogen's revenue over the trailing twelve months?
Over the trailing twelve months, Biogen reported a revenue of $9.66B.
What is the EBITDA for Biogen?
Biogen's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $2.73B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Biogen?
Biogen has a free cash flow of $2.70B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Biogen have, and what sector and industry does it belong to?
Biogen employs approximately 7,500 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Biogen's shares?
The free float of Biogen is 146.64M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $32.63B
- EPS (TTM)
- $5.647
- Free Float
- 146.64M
- P/E ratio (TTM)
- 39.11
- Revenue (TTM)
- $9.66B
- EBITDA (TTM)
- $2.73B
- Free Cashflow (TTM)
- $2.70B
Pricing
- 1D span
- $218.30$221.78
- 52W span
- $135.41$225.45
Analyst Ratings
The price target is $238.93 and the stock is covered by 36 analysts.
Buy
24
Hold
11
Sell
1
Information
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
- Employees
- 7,500
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- BIIB
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet